Tuesday, May 14, 2019

Targeted therapy is expensive - How will the market move forward

All of these next generation targeted therapies are bringing unbelievable technology to patients who have no other options.
But does our healthcare system have the ability to deal with the staggering price of these therapies?
There is no shortage of articles questioning this:
Is Gilead’s new CAR-T overpriced or is payer bureaucracy to blame for slow pickup?

I know that I have strong opinions about this topic, but I would be very interested in other opinions.  What do you think?  Is there a path forward, or are we running down a dead-end?

No comments:

Post a Comment